As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Shares of Tonix Pharmaceuticals are trading sharply higher Tuesday morning. The stock is gaining following the release of the company's Q2 financial results and operational update.
Tonix Pharmaceuticals has filed a registration statement to sell up to $500 million in securities. The company's lead drug candidate is for the management of fibromyalgia pain.
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
In his role at Celgene Corp, Hand played a strategic role in transactions including the $74 billion acquisition of Celgene by Bristol Myers Squibb and its subsequent integration.
Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.
Two biotech companies have surged on recent developments, illustrating biotech's volatility and prompting investors to evaluate potential long-term value.
